13 November 2025
GenIP Plc
("GenIP" or the "Company")
Trading Statement
GenIP Plc, a technology consultancy providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to issue the following trading update for the 10-month period ended 31 October 2025.
As anticipated in our half year update, GenIP's performance has strengthened markedly in the second half. Since 30 June 2025, revenue has accelerated as the prepaid orders for AI-powered analytical assessments are delivered to clients.
The Company has achieved revenues of $408K for the 10 months to 31 October, up from $126k in H1 2025.
Gross margin improved to 27%, compared to 18% in H1 2025.
GenIP continues to work on further increasing gross margins through new contracts and strategic partnerships.
Melissa Cruz, CEO of GenIP, commented:
"GenIP is scaling with margin, data and strategic reach. GenIP revenue has tripled to $408k over 10 months, with gross margin rising from 18% to 27%, demonstrating operating leverage and scalable economics.
Since IPO, we have launched Invention Validator, secured strategic partnerships with technology parks and venture studios and expanded leadership in talent services. Our appointment as Chile's official Green Tech transfer partner connects us with over 400 organisations, accelerating corporate adoption and international reach.
These initiatives are driving repeat orders and inbound referrals, and expansion across 25 countries.
We are consolidating our services and platform under the GenIP.ai brand to create a unified client experience and recurring revenue engine. Automation, data analytics, and proprietary insights will drive margin expansion and validate our model. A SaaS model is the next goal to create a scalable decision-support infrastructure for innovation across academia and industry."
For further information regarding GenIP, please visit www.genip.ai, or contact:
| GenIP Plc Melissa Cruz, CEO |
|
Via Redchurch Communications |
| |
|
|
| Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew Price
|
|
Tel: +44 (0) 20 7628 3396
|
| AlbR Capital Limited (Broker) Colin Rowbury Jon Belliss |
|
Tel: +44 (0)20 7399 9427
|
| Redchurch Communications (Financial PR) John Casey
|
|
|
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
Notes to Editors
About GenIP
GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
| Service |
Description |
Value Proposition |
| Invention Intelligence Product Suite |
AI-powered market intelligence reports assessing the commercial potential of emerging technologies |
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
| Talent and Executive Search Services |
Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership |
De-risks scaling by aligning technical vision with proven executive capability |
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
● Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
● Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
● Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
Forward looking statements
Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.
Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".
For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.
-ENDS-